Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Blood (2024) 144 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2024-207545

Published: 2024

Journal Articles

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2024) 144 (Supplement 1): 4942.

https://doi.org/10.1182/blood-2024-204672

Published: 2024

Journal Articles

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Blood (2023) 142 (Supplement 1): 4986.

https://doi.org/10.1182/blood-2023-185685

Published: 2023

Journal Articles

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2023) 142 (Supplement 1): 657.

https://doi.org/10.1182/blood-2023-182823

Published: 2023

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Blood (2022) 140 (Supplement 1): 4409–4411.

https://doi.org/10.1182/blood-2022-156390

Published: 2022

Journal Articles

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2022) 140 (Supplement 1): 2110–2112.

https://doi.org/10.1182/blood-2022-162277

Published: 2022

Journal Articles

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Ali Bazarbachi, Jacques-Emmanuel Galimard, Myriam Labopin, Iman Abou Dalle, Bruno Lioure, Johan A. Maertens, Maija Itälä-Remes, Maria Pilar Gallego Hernanz, Gesine Bug, Josep-Maria Ribera, Alain Gadisseur, Christoph Schmid, Xavier Poiré, Manuel Jurado Chacón, Frederic Baron, Eolia Brissot, Arnon Nagler, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 735–736.

https://doi.org/10.1182/blood-2022-162162

Published: 2022

Journal Articles

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Blood (2019) 134 (Supplement_1): 4161.

https://doi.org/10.1182/blood-2019-127923

Published: 2019

Journal Articles

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Timothy Devos, Koen Theunissen, Fleur Samantha Benghiat, Alain Gadisseur, Stef Meers, Dominik Selleslag, Gaëtan Vanstraelen, Pierre Zachée, Marc André, Philippe Lewalle, MD, Mia Janssen, Rik Schots, Koen Van Eygen, Alain Kentos, Marie Lejeune, Agnes Triffet, Inge Vrelust, Carolina Kuipers, Violaine Havelange

Blood (2018) 132 (Supplement 1): 1744.

https://doi.org/10.1182/blood-2018-99-114070

Published: 2018

Journal Articles

Comparison of the Power of Procalcitonin and C-Reactive Protein to Differentiate between Different Etiologies of Febrile Neutropenia in Patients with Prolonged Profound Neutropenia

Anke Verlinden, MD, Véronique De Vroey, Ella Roelant, Ann L. R. Van de Velde, MD, Zwi Berneman, MD PhD, Wilfried Schroyens, MD PhD, Alain Gadisseur, MD PhD

Blood (2017) 130 (Supplement 1): 3221.

https://doi.org/10.1182/blood.V130.Suppl_1.3221.3221

Published: 2017

Journal Articles

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

Liliana Baila, Stefan Suciu, Petra Muus, Sergio Amadori, Michel Delforge, Gert Ossenkoppele, Dominik L.D. Selleslag, Antoine Thyss, Hilde Demuynk, Alain Gadisseur, P. Vermeulen, Carla De Boer, Heinz Zwierzina, T.M. de Witte

Blood (2007) 110 (11): 1456.

https://doi.org/10.1182/blood.V110.11.1456.1456

Published: 2007

Journal Articles

The Survival of Multiple Myeloma Patients: A Single Institution Study.

Zwi N. Berneman, MD, PhD, An-Sofie Verstraete, MD, Alain Gadisseur, MD, Ann Van de Velde, MD, Wilfried A. Schroyens, MD, PhD

Blood (2004) 104 (11): 5223.

https://doi.org/10.1182/blood.V104.11.5223.5223

Published: 2004

Journal Articles

Immunotargetting of the Wilms’ Tumor WT1 Antigen for Dendritic Cell and B-Cell-Based Vaccination of Leukemia.

Zwi N. Berneman, MD, PhD, Ann Van Driessche, BSc, Peter Ponsaerts, PhD, Liquan Gao, MD, Hans J. Stauss, MD, PhD, Wilfried A. Schroyens, MD, PhD, Ann Van de Velde, MD, Alain Gadisseur, MD, Marc Lenjou, MT, Griet Nijs, MT, Dirk R. Van Bockstaele, PhD, Viggo F. Van Tendeloo, PhD

Blood (2004) 104 (11): 2541.

https://doi.org/10.1182/blood.V104.11.2541.2541

Published: 2004

NARROW

Autologous Hematopoietic Stem Cell Transplantation in Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Frequency and Impact of Somatic Mutations Alone or in Combination on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Large Study on Behalf of the EBMT Acute Leukemia Working Party

A Multi-Center Retrospective Analysis of Outcomes Post Allogeneic Stem Cell Transplantation in AML Patients with TET2 Mutations: A Study on Behalf of the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Frequency and Impact of Pre-Transplant Somatic Co-Occurring Mutations on Clinical Outcomes of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation: On Behalf of the EBMT Acute Leukemia Working Party

Real-Life Outcomes of Ponatinib Treatment in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Data from a Nationwide Belgian Registry

Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry

Comparison of the Power of Procalcitonin and C-Reactive Protein to Differentiate between Different Etiologies of Febrile Neutropenia in Patients with Prolonged Profound Neutropenia

Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023).

The Survival of Multiple Myeloma Patients: A Single Institution Study.

Immunotargetting of the Wilms’ Tumor WT1 Antigen for Dendritic Cell and B-Cell-Based Vaccination of Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only